Harness Therapeutics appoints Dr Heather Preston as Chair and Secures New Funding from Ono Venture Investment to Accelerate Delivery of Transformational Neurodegeneration Pipeline

03/02/2025

Dr Heather Preston, seasoned healthcare investor with over 30 years’ experience as a scientist, physician, management consultant, and Board adviser, joins as Chair

Funding recognises Harness’ significant progress in unexplored targets for CNS disease and accelerates selection of clinical candidate for lead programme (FAN1) in Huntington’s Disease

Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces it has appointed Dr Heather Preston as new Non-Executive Chair, and has secured further funding to progress its lead programme in Huntington’s Disease. This brings on board pharmaceutical investor Ono Ventures Investment, joined by existing investors, Takeda Ventures, SV Health Investors’ Dementia Discovery Fund and Epidarex Capital.

Click below to read the full article.